Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Trends in Biochemical Sciences|June 28, 2016
Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene TranscriptionAristeidis E Boukouris, Sotirios D Zervopoulos, Evangelos D Michelakis
Frontiers in Immunology|February 27, 2023
Case report: The devil was hidden in the mastocytes - an unusually fulminant case of indolent systemic mastocytosis in a 45-year-old patient, missed for almost 20 yearsAristeidis E Boukouris, Ioannis Michelakis, Dionysios Metaxas, et al.
Frontiers in Oncology|February 12, 2025
Case report: a rare case of diffusely metastatic <i>BRAF</i> V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid glandAristeidis E Boukouris, Ioannis Kokkinakis, Elias Drakos, et al.
Critical Reviews in Oncology/Hematology|March 30, 2022
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 updateAristeidis E Boukouris, Maria Theochari, Dimitra Stefanou, et al.
Molecular Cell|March 4, 2022
MFN2-driven mitochondria-to-nucleus tethering allows a non-canonical nuclear entry pathway of the mitochondrial pyruvate dehydrogenase complexSotirios D Zervopoulos, Aristeidis E Boukouris, Bruno Saleme, et al.
NPJ Precision Oncology|June 13, 2025
A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancerAristeidis E Boukouris, Kleita Michaelidou, Simon A Joosse, et al.
Science Translational Medicine|February 8, 2019
Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicityBruno Saleme, Vikram Gurtu, Yongneng Zhang, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 30, 2020
Interaction with p53 explains a pro-proliferative function for VHL in cancerAdam Kinnaird, Aristeidis E Boukouris, Bruno Saleme, et al.
Critical Reviews in Oncology/Hematology|January 31, 2025
Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial resultsDimitrios C Ziogas, Charalampos Theocharopoulos, Katerina Aravantinou, et al.
Cancers|August 14, 2025
MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung CancerChara Papadaki, Maria Mortoglou, Aristeidis E Boukouris, et al.
Pageof 2